Ocrevus and Zinbryta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ocrevus (ocrelizumab) and Zinbryta (daclizumab). Common drug interactions include gait disturbance among females and electrolyte imbalance among males.

The phase IV clinical study analyzes what interactions people have when they take Ocrevus and Zinbryta. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Zinbryta?

Zinbryta has active ingredients of daclizumab. eHealthMe is studying from 2,382 Zinbryta users. Check the latest studies of Zinbryta.

On Jul, 09, 2026

25 people who take Ocrevus and Zinbryta together, and have interactions are studied.

What are the common drug interactions of Ocrevus and Zinbryta, by gender? *:

female:

Gait disturbance
Fatigue (feeling of tiredness)
Balance disorder
Fall
Sleep disorder
Arthralgia (joint pain)
Asthenia (weakness)
Influenza
Multiple sclerosis relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
Pneumonia

male:

Electrolyte imbalance
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Rash generalised (rash on most of body parts)
Seborrhoeic keratosis (noncancerous (benign) skin growths that some people develop as they age. they often appear on the back or chest)
Syncope (loss of consciousness with an inability to maintain postural tone)
Vision blurred
Adverse drug reaction
Loss of consciousness
Urinary tract infection
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)

What are the common drug interactions of Ocrevus and Zinbryta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Breast cancer
Muscle disorder (muscle disease)
Paresis (a condition of muscular weakness)

40-49:

Fatigue (feeling of tiredness)
Electrolyte imbalance
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Urinary tract infection
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Fall
Syncope (loss of consciousness with an inability to maintain postural tone)
Anaphylactic reaction (serious allergic reaction)
Cardiac failure
Menstrual disorder (disease of menstrual cycle)

50-59:

Fatigue (feeling of tiredness)
Hypersensitivity
Lichenoid keratosis (a skin disorder described by rapid growing, reddish to brown, benign (noncancerous) lesion on the skin)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Photosensitivity reaction
Pruritus generalised (generalized itching)
Rash generalised (rash on most of body parts)
Seborrhoeic keratosis (noncancerous (benign) skin growths that some people develop as they age. they often appear on the back or chest)
Vision blurred

60+:

Arthralgia (joint pain)
Asthenia (weakness)
Cough
Depression
Disturbance in attention
Dizziness
Dysphagia (a condition in which swallowing is difficult or painful)
Fatigue (feeling of tiredness)
Gait disturbance
Hyperglycaemia (high blood sugar)

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 20 people, 80.00%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 10 people, 40.00%
Gait Disturbance: 7 people, 28.00%
Pain: 2 people, 8.00%
Muscle Spasms (muscle contraction): 2 people, 8.00%
High Blood Pressure: 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and Zinbryta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously